Lakewood-Amedex Biotherapeutics Inc.

S-1/A amended

Lakewood-Amedex Biotherapeutics Inc. is registering the resale of up to 4,689,177 shares of common stock by registered stockholders for a direct listing on Nasdaq. The offering involves a novel direct listing structure without a traditional underwritten IPO, with no proceeds going to the company. The company engaged RBW Capital Partners as a financial advisor and placement agent for a Series C Preferred Stock private placement, with conversion terms tied to a floor price of $1.00. The listing is contingent on Nasdaq approval, and the company faces risks related to market volatility and lack of public trading history.

S-1/A amended

Lakewood-Amedex Biotherapeutics Inc. is conducting a direct listing on Nasdaq, enabling registered stockholders to resell up to 4,689,177 shares of common stock without a traditional IPO underwriting. The company engaged RBW Capital Partners as a financial advisor and placement agent for a Series C Preferred Stock private placement, with plans to file a resale registration for underlying common stock post-listing. The offering hinges on Nasdaq approval, with risks including listing uncertainty, price volatility, and lack of public market liquidity. The company qualifies as an emerging growth company with reduced disclosure requirements.

S-1/A amended

Lakewood-Amedex Biotherapeutics Inc. is registering shares for a direct listing on Nasdaq, allowing existing stockholders to resell up to 4,689,177 common shares without an underwritten offering. The company engaged RBW Capital Partners as a financial advisor and placement agent for a private placement of Series C Preferred Stock. The listing is conditional on Nasdaq approval, with risks including market volatility, lack of public market, and uncertainty around the listing process.

S-1/A amended

Lakewood-Amedex Biotherapeutics Inc. is registering shares for a direct listing on Nasdaq, bypassing a traditional IPO. The filing details the resale of 4,689,177 common shares by existing stockholders, with no proceeds going to the company. The company engaged RBW Capital Partners as a financial advisor and placement agent for a private placement of Series C Preferred Stock, which is convertible into common stock. The direct listing hinges on Nasdaq approval, with risks tied to market volatility and listing uncertainties.

S-1/A amended

Lakewood-Amedex Biotherapeutics Inc. is registering shares for a direct listing on Nasdaq without a traditional underwritten offering. The filing details the resale of 4,689,177 common shares by existing stockholders, with no proceeds to the company. The company engaged RBW Capital Partners as a financial advisor and placement agent for a Series C Preferred Stock private placement, which converts to common stock at a variable price. The listing hinges on Nasdaq approval, with risks including market volatility and uncertainty of approval.

S-1 filed

Lakewood-Amedex Biotherapeutics Inc. filed an S-1 registration statement for a direct listing on Nasdaq, enabling registered stockholders to resell 4,689,177 shares of common stock without a firm-commitment underwriting. The company engaged RBW Capital Partners as financial advisor and placement agent for a Series C Preferred Stock private placement, with plans to list common stock under the symbol 'LABT'. The filing highlights risks related to Nasdaq approval, market volatility, and the novel direct listing structure.

DRS/A amended

Lakewood-Amedex Biotherapeutics Inc. filed an S-1/A registration statement for a direct listing on Nasdaq, disclosing details about the resale of 3,897,723 common shares by registered stockholders. The filing highlights the company's direct listing strategy without a traditional underwritten offering, emphasizing the novel price-setting mechanism via Nasdaq's Current Reference Price. It also outlines a private placement of Series C Preferred Stock convertible into common stock and compensation arrangements with financial advisor RBW Capital Partners, including 269,411 advisory shares. The company remains an emerging growth company with reduced reporting requirements.

DRS filed

Lakewood-Amedex Biotherapeutics Inc. filed a Form S-1 registration statement for a direct listing on Nasdaq, enabling existing shareholders to resell 26,693,023 shares of common stock without a traditional underwritten offering. The company engaged RBW Capital Partners as a financial advisor for the listing, which involves a novel price-setting mechanism by Nasdaq. The filing emphasizes risks related to the unproven direct listing process, lack of market liquidity, and dependence on Nasdaq approval. The company remains an emerging growth entity with limited operating history and no commercialized products.